Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the USA with a 5-year survival rate less than 3% to 5%. Gemcitabine remains as a standard care for PDAC patients. Although protein neddylation is abnormally activated in many human cancers, whether neddylation dys...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hua, Zhou, Weihua, Li, Lihui, Wu, Jianfu, Liu, Xiaoli, Zhao, Lili, Jia, Lijun, Sun, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440286/
https://www.ncbi.nlm.nih.gov/pubmed/28535453
http://dx.doi.org/10.1016/j.neo.2017.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440286/
https://www.ncbi.nlm.nih.gov/pubmed/28535453
http://dx.doi.org/10.1016/j.neo.2017.04.003

Ejemplares similares